中华眼底病杂志

中华眼底病杂志

老年性黄斑变性治疗方法试验比较的启示

查看全文

  老年性黄斑变性(AMD)治疗方法试验比较(CATT)结果显示,倍伐单抗(商品名Avastin)和雷珠单抗按照相同的给药计划给药,临床观察12个月,患者视力效果等同。雷珠单抗按需求给药组在视力上与每一个月给药组等同。倍伐单抗是一个对抗血管内皮生长因子(VEGF)的全长单克隆抗体(MAb),能够对抗VEGF所有有生物活性的亚型,阻止VEGF和受体结合;雷珠单抗是把倍伐单抗和抗原结合部的片段分离出来,在临床上完成了4期I/II观察的制剂。二者在价格上悬殊巨大,倍伐单抗 50美元/支,而雷珠单抗2000美元/支。在如此价格差距下,如果倍伐单抗能够改善视力和黄斑解剖,其临床应用的性价比会优于雷珠单抗。CATT研究结果支持全球继续使用玻璃体腔入路的给药途径使用倍伐单抗作为对雷珠单抗的一种廉价选择。

  Comparison of age-related macular degeneration treatments trials (CATT) reported the results of the first year: At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule. Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly. Bevacizumab is a monoclonal antibody (MAb) and full-length antiVEGF antibody that successfully prevents binding of all the biologically active isoforms of VEGF to the receptor. Ranibizumab is a isolated antigenbinding fragment (Fab) from bevacizumab using recombinant genetic techniques. Ranibizumab has been clinically evaluated in 4 Phase I/II studies. The cost of Avastin is
50 per dose compared with
2000 per dose for Ranibizumab. If Avastin could improve vision and macular anatomy, then it would not only be clinically superior to Ranibizumab. The CATT data support the continued global use of intravitreal bevacizumab as an effective, low-cost alternative to ranibizumab, particularly for patients paying all costs out of pocket.

关键词: 述评

Key words: Editorial

引用本文: 黎晓新. 老年性黄斑变性治疗方法试验比较的启示. 中华眼底病杂志, 2011, 27(3): 205-206. doi: 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,